4.00
price down icon2.44%   -0.10
after-market Dopo l'orario di chiusura: 4.05 0.05 +1.25%
loading
Precedente Chiudi:
$4.10
Aprire:
$4.12
Volume 24 ore:
392.74K
Relative Volume:
0.34
Capitalizzazione di mercato:
$143.94M
Reddito:
$317.00K
Utile/perdita netta:
$-53.47M
Rapporto P/E:
-2.1164
EPS:
-1.89
Flusso di cassa netto:
$-49.31M
1 W Prestazione:
-6.98%
1M Prestazione:
+36.05%
6M Prestazione:
+94.17%
1 anno Prestazione:
+247.83%
Intervallo 1D:
Value
$4.00
$4.25
Intervallo di 1 settimana:
Value
$3.95
$4.35
Portata 52W:
Value
$1.00
$4.60

Immuneering Corp Stock (IMRX) Company Profile

Name
Nome
Immuneering Corp
Name
Telefono
617-500-8080
Name
Indirizzo
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Name
Dipendente
54
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-19
Name
Ultimi documenti SEC
Name
IMRX's Discussions on Twitter

Confronta IMRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
IMRX
Immuneering Corp
4.00 151.86M 317.00K -53.47M -49.31M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Immuneering Corp Stock (IMRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-13 Downgrade Morgan Stanley Equal-Weight → Underweight
2024-03-15 Downgrade Jefferies Buy → Hold
2024-03-15 Reiterato Needham Buy
2024-03-15 Downgrade TD Cowen Outperform → Market Perform
2023-12-01 Iniziato Needham Buy
2023-06-26 Ripresa Oppenheimer Outperform
2023-04-19 Aggiornamento Mizuho Neutral → Buy
2023-04-19 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2023-03-30 Iniziato Mizuho Neutral
2023-02-03 Downgrade Morgan Stanley Equal-Weight → Underweight
2022-07-08 Iniziato Chardan Capital Markets Buy
2022-04-01 Iniziato Oppenheimer Outperform
2022-01-07 Iniziato Piper Sandler Overweight
Mostra tutto

Immuneering Corp Borsa (IMRX) Ultime notizie

pulisher
Jul 22, 2025

What analysts say about Immuneering Corporation stockFree Stock Market Return Analysis - Autocar Professional

Jul 22, 2025
pulisher
Jul 19, 2025

What drives Immuneering Corporation stock priceFastest-growing stock picks - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Analysts Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $13.25 - Defense World

Jul 19, 2025
pulisher
Jul 18, 2025

Is Immuneering Corporation a good long term investmentSuperior stock growth - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Immuneering Corporation stock price move sharplyTop Gaining Low Risk Assets - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Immuneering Corporation stock attracts strong analyst attentionShort Term Profit Focus - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow

Jul 10, 2025
pulisher
Jul 09, 2025

Revolutionary Cancer Drug Gets Patent Protection Until 2042: Clinical Data Shows 94% Survival vs 67% Standard Care - Stock Titan

Jul 09, 2025
pulisher
Jul 07, 2025

Immuneering director Hausman buys IMRX stock worth $19,862 By Investing.com - Investing.com South Africa

Jul 07, 2025
pulisher
Jul 07, 2025

Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock By Investing.com - Investing.com South Africa

Jul 07, 2025
pulisher
Jul 07, 2025

Immuneering director Hausman buys IMRX stock worth $19,862 - Investing.com

Jul 07, 2025
pulisher
Jul 01, 2025

Insider Buying: Thomas Schall Acquires Additional Shares of Immu - GuruFocus

Jul 01, 2025
pulisher
Jun 27, 2025

Immuneering (IMRX) Soars 10.66% on Positive Trial Data, Insider Buying - AInvest

Jun 27, 2025
pulisher
Jun 26, 2025

At $3.02 Price, Immuneering Corp (IMRX) Is Sitting And Waiting - Stocksregister

Jun 26, 2025
pulisher
Jun 25, 2025

Jefferies raises Immuneering price target to $3.50 from $1.50 on cancer data - Investing.com

Jun 25, 2025
pulisher
Jun 24, 2025

Insider Buying: Brett Hall Acquires Additional Shares of Immuneering Corp (IMRX) - GuruFocus

Jun 24, 2025
pulisher
Jun 24, 2025

Immuneering (IMRX) CBO Brakewood buys $4804 in shares - Investing.com

Jun 24, 2025
pulisher
Jun 23, 2025

Immuneering (IMRX) director Feinberg buys $63k in shares - Investing.com

Jun 23, 2025
pulisher
Jun 20, 2025

Immuneering (IMRX) CEO Zeskind buys $50k+ in shares By Investing.com - Investing.com UK

Jun 20, 2025
pulisher
Jun 19, 2025

Immuneering (NASDAQ:IMRX) Receives Buy Rating from Needham & Company LLC - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com

Jun 18, 2025
pulisher
Jun 17, 2025

Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering stock rises after positive pancreatic cancer trial data - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering (IMRX) Reports Promising Phase 2a Trial Results for Pancreatic Cancer Treatment | IMRX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Pancreatic Cancer Breakthrough: New Drug Shows 94% Survival Rate vs 67% Standard Care in Phase 2a Trial - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering Stock Soars 25.74% on Promising Cancer Trial Results - AInvest

Jun 17, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting - Investing.com Australia

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Purchases 10,126 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Immuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLC - Defense World

Jun 12, 2025
pulisher
Jun 06, 2025

Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Needham Maintains Buy Rating on IMRX with Price Target of $9.00 - GuruFocus

Jun 05, 2025
pulisher
May 29, 2025

Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Immuneering Corporation to Present at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq

May 29, 2025
pulisher
May 15, 2025

‘Take the Plunge,’ Says Top Investor About Intel Stock - The Globe and Mail

May 15, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World

May 07, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.00 | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks

May 07, 2025
pulisher
May 06, 2025

Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus

May 06, 2025

Immuneering Corp Azioni (IMRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):